Cargando…

Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells

Radioimmunotherapy (RIT) is an emerging treatment option for non-Hodgkin lymphoma (NHL) producing higher overall response and complete remission rates compared with unlabelled antibodies. However, the majority of patients treated with conventional or myeloablative doses of radiolabelled antibodies r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roscher, Mareike, Hormann, Inis, Leib, Oliver, Marx, Sebastian, Moreno, Josue, Miltner, Erich, Friesen, Claudia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2013
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712568/ https://www.ncbi.nlm.nih.gov/pubmed/23474846

Ejemplares similares

Opioid receptor activation triggering downregulation of cAMP improves effectiveness of anti-cancer drugs in treatment of glioblastoma
por: Friesen, Claudia, et al.
Publicado: (2014)

Cell death sensitization of leukemia cells by opioid receptor activation
por: Friesen, Claudia, et al.
Publicado: (2013)

Studies of $\alpha$-spectra in $^{221}Fr, ^{217}At, ^{213}Bi$ and $^{213}Po$ decays
por: Chumin, V G, et al.
Publicado: (1997)

(213)Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
por: Sathekge, Mike, et al.
Publicado: (2017)

Level structure in $^{213}Bi$
por: Chumin, V G, et al.
Publicado: (1996)

Alpha-Particle Emitting (213)Bi-Anti-EGFR Immunoconjugates Eradicate Tumor Cells Independent of Oxygenation
por: Wulbrand, Christian, et al.
Publicado: (2013)

Optimizing labelling conditions of (213)Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy
por: Chan, Ho Sze, et al.
Publicado: (2016)

Radioimmunotherapy of micrometastases in lung with vascular targeted(213)Bi
por: Kennel, S J, et al.
Publicado: (1999)

Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotate
por: Chan, Ho Sze, et al.
Publicado: (2016)

Efficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: towards improved alpha-therapeutics
por: Šimeček, Jakub, et al.
Publicado: (2018)

Long-Term Toxicity of (213)Bi-Labelled BSA in Mice
por: Dorso, Laëtitia, et al.
Publicado: (2016)

Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with (213)Bi-substance P analogue
por: Krolicki, Leszek, et al.
Publicado: (2018)

Treatment of Peritoneal Carcinomatosis by Targeted Delivery of the Radio-Labeled Tumor Homing Peptide (213)Bi-DTPA-[F3](2) into the Nucleus of Tumor Cells
por: Drecoll, Enken, et al.
Publicado: (2009)

First‐Generation Bispidine Chelators for (213)Bi(III) Radiopharmaceutical Applications
por: Bruchertseifer, Frank, et al.
Publicado: (2020)

A Radionuclide Generator of High-Purity Bi-213 for Instant Labeling
por: Ermolaev, Stanislav, et al.
Publicado: (2021)

Therapeutic Performance Evaluation of (213)Bi-Labelled Aminopeptidase N (APN/CD13)-Affine NGR-Motif ([(213)Bi]Bi-DOTAGA-cKNGRE) in Experimental Tumour Model: A Treasured Tailor for Oncology
por: Képes, Zita, et al.
Publicado: (2023)

An Overview of Targeted Alpha Therapy with (225)Actinium and (213)Bismuth
por: Morgenstern, Alfred, et al.
Publicado: (2018)

In Vitro comparison of (213)Bi- and (177)Lu-radiation for peptide receptor radionuclide therapy
por: Chan, Ho Sze, et al.
Publicado: (2017)

ZNF213 Facilitates ER Alpha Signaling in Breast Cancer Cells
por: Yang, Huijie, et al.
Publicado: (2021)

(213)Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
por: Kratochwil, C., et al.
Publicado: (2014)

Therapeutic Efficacy of Alpha-RIT Using a (213)Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal Carcinomatosis
por: Derrien, Aurélie, et al.
Publicado: (2015)

Improved safety and efficacy of (213)Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine
por: Chan, Ho Sze, et al.
Publicado: (2016)

Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance
por: Dudás, József, et al.
Publicado: (2020)

Radium and Francium beam tests to produce 225Ac/ 213Bi generators at CERN-MEDICIS
por: Bruchertseifer, Frank, et al.
Publicado: (2015)

Diverse metabolic response of cancer cells treated with a (213)Bi-anti-EGFR-immunoconjugate
por: Feuerecker, Benedikt, et al.
Publicado: (2021)

Atomic Nanogenerators in Targeted Alpha Therapies: Curie’s Legacy in Modern Cancer Management
por: Roscher, Mareike, et al.
Publicado: (2020)

Cure of Micrometastatic B-Cell Lymphoma in a SCID Mouse Model Using (213)Bi-Anti-CD20 Monoclonal Antibody
por: Havlena, Gregory T., et al.
Publicado: (2023)

Targeted alpha therapy of mCRPC: Dosimetry estimate of (213)Bismuth-PSMA-617
por: Kratochwil, Clemens, et al.
Publicado: (2017)

Options for first line therapy of Hodgkin lymphoma
por: Longley, Jemma, et al.
Publicado: (2019)

MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate
por: Qu, C F, et al.
Publicado: (2004)

α-Radioimmunotherapy with (213)Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma
por: Teiluf, Katharina, et al.
Publicado: (2014)

Study of (213)Bi and (211)Pb Recoils Release from (223)Ra Labelled TiO(2) Nanoparticles
por: Kozempel, Ján, et al.
Publicado: (2022)

Detecting radio- and chemoresistant cells in 3D cancer co-cultures using chromatin biomarkers
por: Pekeč, Tina, et al.
Publicado: (2023)

Preclinical studies of targeted α therapy for breast cancer using (213)Bi-labelled-plasminogen activator inhibitor type 2
por: Allen, B J, et al.
Publicado: (2003)

Nuclear and laser spectroscopy study of the neutron-rich $^{212,213,215,216,217,219,220}$Bi isotopes with LIST
por: Andreyev, Andrei, et al.
Publicado: (2023)

Cubosomal Lipid Formulation for Combination Cancer Treatment: Delivery of a Chemotherapeutic Agent and Complexed α-Particle Emitter (213)Bi
por: Cytryniak, Adrianna, et al.
Publicado: (2022)

Transmembrane TNF-alpha promotes chemoresistance in breast cancer cells
por: Zhang, Zunyue, et al.
Publicado: (2018)

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review
por: Fedele, Roberta, et al.
Publicado: (2015)

Review of Treatment Options for the Management of Advanced Stage Hodgkin Lymphoma
por: Vellemans, Hélène, et al.
Publicado: (2021)

The Molecular Chaperone GRP78/BiP in the Development of Chemoresistance: Mechanism and Possible Treatment
por: Roller, Corinna, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_q79nnt2tqrs95vlhekbfjpgev1